News

The FDA has approved Bayer’s antihemophilic factor [recombinant] PEGylated-aucl, BAY94-9027 (Jivi), for routine prophylactic treatment of hemophilia A in previously treated adults and adolescents aged 12 years or older.

One Cleveland Clinic practitioner describes his real-world experience with the use of mepolizumab in patients with severe eosinophilic asthma.

The investigative therapy reported a relative difference of 48% in brain atrophy reduction versus placebo, but investigators are still uncertain of its benefits.

A class of drugs indicated for use with diet and exercise in patients with type 2 diabetes, has been linked to necrotizing fasciitis of perineum (Fournier’s gangrene).

Stem cell research from the University of Michigan reveals dangerous cardiac effects of a gene mutation in patients with Dravet syndrome.

Investigators in Cincinnati have linked a gene with myelodysplastic syndromes, potentially offering the first step toward a new genetic therapy.

Investigators from McGill University have discovered a new link connecting immune cells and the development of gastric tumors in those with Peutz-Jeghers Syndrome.

A paternal smoking amount of more than 15 cigarettes per day was significantly associated with children's ADHD.

The COMPASS-XT five-year analysis reported that patients treated with the micro-stent experienced statistically significant loss of endothelial cells compared to the patients treated with lone cataract surgery.

Direct-acting antivirals have been a life-changing breakthrough for patients with chronic hepatitis C virus infection. However, the high cost of the drugs has led many patients down a path of appeals and battles with insurers.

A small study found that ketamine decreased symptoms of depression—investigators studied its effects in combination with the opioid-blocker naltrexone compared to a placebo.

A phase 3 trial demonstrates that tafamidis significantly reduced the combination of all-cause mortality and cardiovascular-related hospitalizations in patients with ATTR-CM.

The FDA has granted an orphan drug designation to ReflectionBio's AAV-based gene therapy, the RBIO-101 program (AAV.CYP4V2), for the treatment of Bietti's crystalline dystrophy (BCD).

In 2016, US firearm suicides represented 35.3% of all global firearm suicides—despite the US just comprising 4.3% of the global population.

Early trials have shown promising results for hemophilia therapies and now could be the most promising time for a lasting treatment and possible cure.

Results of an analysis indicate suicidal behavior occurred more often in patients taking an efavirenz-based treatment for HIV than in a control group that had not started treatment.

What a longtime family practitioner in a state that authorizes medical aid in dying has learned through his own experience of the controversial practice.

New insights might help researchers improve the efficacy of LTA4H inhibitors.

Relevant cIAI diagnoses include intra-abdominal abscess, stomach perforation, peritonitis, appendicitis, and more. Eravacycline's efficacy and safety were established in non-inferiority studies comparing it to the widely-used therapies ertapenem and meropenem.

The FDA has granted a fast track designation to CX-01 for the treatment of patients over 60 years of age receiving induction therapy for newly-diagnosed AML.

The FDA has granted a rare pediatric disease designation to AAV-CNGA3 for the treatment of patients with achromatopsia due to mutations in the CNGA3 gene.

As more physicians are caring for transgender patients, many are finding they are unprepared and they lack the training, skills, and resources to do so, according to the authors of a recent review article.

The FDA has approved ibrutinib (IMBRUVICA) plus rituximab (RITUXAN) for the treatment of adult patients with Waldenström's macroglobulinemia, a rare and incurable type of non-Hodgkin's lymphoma.

Patients whose direct-acting antiviral treatment failed are finding hope in a new combination of 3 existing hepatitis C virus drugs.

A new survey found that Clostridium difficile infections have a substantial impact on the health-related quality of work, work life, and physical activity of those who are infected.

In a 15,000-plus patient analysis that spanned more than 7 years, aspirin reduced vascular risks in patients—but also increased their rate of major bleeding events.

Patients administered the FDA-approved therapy reported tripled rates of weight-loss, along with noninferiority for risk of major cardiovascular events, over 1 year and an extension period.

Stay up-to-date on the latest rare disease news by checking out our top 5 articles of the week.